Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2010, 3(10), 3101-3126; doi:10.3390/ph3103101
Review

Endocannabinoids and Schizophrenia

,
,
 and *
Received: 10 September 2010; Accepted: 25 September 2010 / Published: 8 October 2010
(This article belongs to the Special Issue Cannabinoids)
View Full-Text   |   Download PDF [183 KB, uploaded 8 October 2010]
Abstract: The endocannabinoids anandamide and 2-arachydonoylglycerol (2-AG) are lipids naturally derived from membrane precursors which bind cannabinoid receptors (CB1, CB2). This endocannabinoid system is disturbed in schizophrenia. Indeed, there seems to be an association between schizophrenia and polymorphisms of the CB1 receptor gene. Moreover, CB1 receptors are found in higher density in the prefrontal cortex, hippocampus and basal ganglia of patients with schizophrenia. Similarly, anandamide levels are increased in the cerebrospinal fluid (CSF) and in the serum of schizophrenia patients, including during the prodromal state, suggesting that they may play a protective role in psychosis homeostasis. Future studies are needed to further explore the role of the endocannabinoid system in the pathophysiology of schizophrenia.
Keywords: endocannabinoids; schizophrenia; cannabis; drug abuse; metabolism endocannabinoids; schizophrenia; cannabis; drug abuse; metabolism
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Desfossés, J.; Stip, E.; Bentaleb, L.A.; Potvin, S. Endocannabinoids and Schizophrenia. Pharmaceuticals 2010, 3, 3101-3126.

AMA Style

Desfossés J, Stip E, Bentaleb LA, Potvin S. Endocannabinoids and Schizophrenia. Pharmaceuticals. 2010; 3(10):3101-3126.

Chicago/Turabian Style

Desfossés, Joëlle; Stip, Emmanuel; Bentaleb, Lahcen Ait; Potvin, Stéphane. 2010. "Endocannabinoids and Schizophrenia." Pharmaceuticals 3, no. 10: 3101-3126.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert